Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Novo Nordisk and Eli Lilly's motion to dismiss took aim at most of the counts asserted in the plaintiffs’ master long-form ...

For the last couple of years, the pharmaceutical sector has become infatuated with glucagon-like peptide 1 ... most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight ...

Eli Lilly makes some of the most powerful weight ... Like Ozempic, the new pill is designed to mimic the glucagon-like peptide 1 hormone that our bodies produce naturally, albeit in very small ...